The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology

Volumn 66, Issue 2, 2012, Pages

  Kimball, Alexa Boer ^a   Yu, Andrew P ^b   Signorovitch, James ^b   Xie, Jipan ^b   Tsaneva, Magda ^b   Gupta, Shiraz R ^c   Bao, Yanjun ^c   Mulani, Parvez M ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

adalimumab; biologic therapy; cost savings; disease severity; psoriasis; work productivity and activity impairment

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ASSOCIATION; DISEASE SEVERITY; EMPLOYMENT STATUS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISABILITY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE INDEX; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WORK DISABILITY; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR PSORIASIS;

ABSENTEEISM; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; EFFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT; TREATMENT OUTCOME; WORK;

EID: 84855827132     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.10.020     Document Type: Article

References (38)

1. S.K. Kurd, and J.M. Gelfand The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004 J Am Acad Dermatol 60 2009 218 224
2. P.F. Adams, G.E. Hendershot, and M.A. Marano Current estimates from the national health interview survey, 1996 Vital Health Stat 10 200 1999 1 203
3. M.W. Greaves, and G.D. Weinstein Treatment of psoriasis N Engl J Med 332 1995 581 588
4. A.B. Kimball, C. Jacobson, S. Weiss, M.G. Vreeland, and Y. Wu The psychosocial burden of psoriasis Am J Clin Dermatol 6 2005 383 392 (Pubitemid 43128290)
5. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850 (Pubitemid 351509656)
6. The Society for Investigative Dermatology and the American Academy of Dermatology Association. The burden of skin diseases 2004. Available from: URL: http://www.sidnet.org/pdfs/Burden%20of%20Skin%20Diseases%202004.pdf. Accessed April 13, 2009.
7. National Psoriasis Foundation. Benchmark survey on psoriasis and psoriatic arthritis: summary of top line results. Available from: URL: http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf. Accessed April 13, 2009.
8. J.M. Schmitt, and D.E. Ford Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis Dermatology 213 2006 102 110 (Pubitemid 44215193)
9. D.J. Pearce, S. Singh, R. Balkrishnan, A. Kulkarni, A.B. Fleischer, and S.R. Feldman The negative impact of psoriasis on the workplace J Dermatolog Treat 17 2006 24 28 (Pubitemid 43247304)
10. J.F. Fowler, M.S. Duh, L. Rovba, S. Buteau, L. Pinheiro, and F. Lobo The impact of psoriasis on health care costs and patient work loss J Am Acad Dermatol 59 2008 772 780
11. K. Reich, F.O. Nestle, Y. Wu, M. Bala, D. Eisenberg, and C. Guzzo Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis Eur J Dermatol 17 2007 381 386 (Pubitemid 47425903)
12. M.C. Reilly, A.S. Zbrozek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
13. M. Prasad, P. Wahlqvist, R. Shikiar, and Y.C. Shih A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective Pharmacoeconomics 22 2004 225 244 (Pubitemid 38393392)
14. M.C. Reilly, P.T. Lavin, K.H. Kahler, and D.M. Pariser Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment-Chronic Hand Dermatitis questionnaire in chronic hand dermatitis J Am Acad Dermatol 48 2003 128 130 (Pubitemid 36091547)
15. M.C. Reilly, K.L. Gooch, R.L. Wong, H. Kupper, and D. van der Heijde Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis Rheumatology (Oxford) 49 2010 812 819
16. M.C. Reilly, L. Gerlier, Y. Brabant, and M. Brown Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease Clin Ther 30 2008 393 404 (Pubitemid 351474386)
17. M.C. Reilly, A. Bracco, J.F. Ricci, J. Santoro, and T. Stevens The validity and accuracy of the Work Productivity and Activity Impairment Questionnaire-Irritable Bowel Syndrome version (WPAI: IBS) Aliment Pharmacol Ther 20 2004 459 467 (Pubitemid 39120258)
18. N. Meyer, C. Paul, D. Feneron, I. Bardoulat, C. Thiriet, and C. Camara Psoriasis: an epidemiological evaluation of disease burden in 590 patients J Eur Acad Dermatol Venereol 24 2010 1075 1082
19. Y. Wu, D. Mills, and M. Bala Impact of psoriasis on patients' work and productivity: a retrospective, matched case-control analysis Am J Clin Dermatol 10 2009 407 410
20. B. Chan, B. Hales, N. Shear, V. Ho, C. Lynde, and Y. Poulin Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis J Cutan Med Surg 13 2009 192 197
21. D.A. Revicki, M.K. Willian, A. Menter, K.B. Gordon, A.B. Kimball, and C.L. Leonardi Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis J Dermatolog Treat 18 2007 341 350 (Pubitemid 350223202)
22. D. Revicki, M.K. Willian, J.H. Saurat, K.A. Papp, J.P. Ortonne, and C. Sexton Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis Br J Dermatol 158 2008 549 557 (Pubitemid 351239150)
23. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
24. Reilly Associates. WPAI scoring. Available from: URL: http://www.reillyassociates.net/WPAI-Scoring.html. Accessed April 27, 2009.
25. T. Fredriksson, and U. Pettersson Severe psoriasis: oral therapy with a new retinoid Dermatologica 157 1978 238 244 (Pubitemid 8387357)
26. The European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis, 2004. Available from: URL: http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf. Accessed December 11, 2009.
27. Ko H-S. Clinical trial design in psoriasis. Presented at: 49th Meeting of the Dermatologic and Ophthalmologic Advisory Committee; March 20, 1998; Bethesda, MD.
28. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216 (Pubitemid 24194579)
29. M.K. Basra, R. Fenech, R.M. Gatt, M.S. Salek, and A.Y. Finlay The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results Br J Dermatol 159 2008 997 1035
30. Y. Hongbo, C.L. Thomas, M.A. Harrison, M.S. Salek, and A.Y. Finlay Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 125 2005 659 664
31. National Institute for Health and Clinical Excellence. Adalimumab for the treatment of adults with psoriasis. Available from: URL: http://www.nice.org. uk/nicemedia/pdf/TA146Guidance.pdf. Accessed November 13, 2009.
32. M. Lebwohl, K. Papp, C. Han, B. Schenkel, N. Yeilding, and Y. Wang Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial Br J Dermatol 162 2010 137 146
33. S.P. Sivanesan, S. Gattu, J. Hong, A. Chavez-Frazier, G.D. Bandow, and F. Malick Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks J Am Acad Dermatol 61 2009 793 798
34. P.C. van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
35. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566 (Pubitemid 351239154)
36. G.R. Norman, J.A. Sloan, and K.W. Wyrwich Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation Med Care 41 2003 582 592
37. US Department of Labor, Bureau of Labor Statistics. National occupational employment and wage estimates. 2007. Available from: URL: http://www.bls.gov/ oes/current/oes-nat.htm#b00-0000. Accessed April 13, 2009.
38. E.J. Horn, K.M. Fox, V. Patel, C.F. Chiou, F. Dann, and M. Lebwohl Association of patient-reported psoriasis severity with income and employment J Am Acad Dermatol 57 2007 963 971 (Pubitemid 350087343)